Page 11 - Dupilumab Development Programdupilumab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dupilumab development programdupilumab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dupilumab Development Programdupilumab Today - Breaking & Trending Today

Dupilumab Cuts COPD Exacerbations by 30% in Phase 3 Trial

Dupilumab is the first biologic to significantly improve lung function in chronic obstructive pulmonary disease (COPD), according to topline results released Thursday. ....

United States , Georged Yancopoulos , Respiratory Questionaire , Chronic Obstructive Pulmonary Disease ,

Patient Outcomes Improve on Several Fronts Following Treatment for Prurigo Nodularis

Subanalyses of data from the LIBERTY PN-PRIME and LIBERTY PN-PRIME2 studies illustrate how dupilumab for prurigo nodularis can better patient outcomes, including quality of life and symptom burden. ....

United States , American Academy Of Dermatology Annual Meeting , Dermatology Annual Meeting , Dermatology Life Quality Index , Worst Itch Numeric Rating Scale , Skin Pain Numeric Rating Scale , Sleep Numeric Rating Scale , Prurigo Nodularis , Pn Prime , Pn Prime2 ,

Sanofi - Aventis Groupe: Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis More than twice as many ....

United States , France General , Eva Schaefer Jansen , Corentine Driancourt , Felix Lauscher , Tarik Elgoutni , Vesna Tosic , Hannah Kwagh , Nathalie Pham , Ericl Simpson , Sally Bain , Francesj Storrs , Science University , Regeneron Pharmaceuticals Inc , Regeneron Genetics Center , Oregon Health , Dupilumab Development Program , Exchange Commission , American Academy Of Dermatology , European Union , American Academy , Medical Dermatology , Investigator Global Assessment Scale , Peak Pruritis Numeric Rating Scale , Modified Total Lesion Sign Score , Hand Eczema Severity Index ,

Sanofi - Aventis Groupe: Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review

Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review More than 300,000 people in the U.S. suffer ....

France General , Dennis Riedl , Eva Schaefer Jansen , Corentine Driancourt , Felix Lauscher , Tammy Allen , Tarik Elgoutni , Vesna Tosic , Nathalie Pham , Sally Bain , Regeneron Pharmaceuticals Inc , Regeneron Genetics Center , Drug Administration , Dupilumab Development Program , Clinical Trial Program , Exchange Commission , Biologics License Application , Regeneron Genetics , Private Securities Litigation Reform Act , Statement Regarding Forward Looking , Forward Looking Statements , Digital Media , Regeneron Pharmaceuticals , Product Candidates ,

Sanofi - Aventis Groupe: Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis

Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis If approved, Dupixent would be the first and only ....

France General , Eva Schaefer Jansen , Corentine Driancourt , Felix Lauscher , Vesna Tosic , Hannah Kwagh , Nathalie Pham , Sally Bain , Priya Nanduri , Regeneron Pharmaceuticals Inc , European Commission Of Dupixent , Regeneron Genetics Center , European Commission , Drug Administration , Dupilumab Development Program , Exchange Commission , European Union , European Medicines Agency , Medicinal Products , Human Use , Private Securities Litigation Reform Act , Statement Regarding Forward Looking , Forward Looking Statements , Digital Media , Regeneron Pharmaceuticals , Product Candidates ,